SPRB - Spruce Bio gains after Neurocrine's Phase 3 win for genetic disorder drug
2023-09-12 14:05:37 ET
More on Spruce
- Seeking Alpha’s Quant Rating on Spruce Biosciences
- Historical earnings data for Spruce Biosciences
- Financial information for Spruce Biosciences
- Spruce Biosciences: H2 2023 Data Could Be A Game Changer For CAH Treatment
- Sizing Up Spruce Biosciences
For further details see:
Spruce Bio gains after Neurocrine’s Phase 3 win for genetic disorder drug